Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Yukari TsubataKana WatanabeRyota SaitoAtsushi NakamuraHiroshige YoshiokaMami MoritaRyoichi HondaNobuhiro KanajiSatoshi OhizumiDaisuke JinguTaku NakagawaKensuke NakazawaAtsuto MouriSusumu TakeuchiNaoki FuruyaYuki AkazawaKiyotaka MiuraEiki IchiharaMakoto MaemondoSatoshi MoritaKunihiko KobayashiTakeshi IsobePublished in: International journal of clinical oncology (2021)
Osimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.